Scynexis Executive Compensation
SCYNEXIS appointed Steven K. Burke, M.D., to its Board of Directors and the Nominating and Corporate Governance Committee. Dr. Burke will receive an annual cash retainer of $45,000 plus $5,000 for committee service, along with initial equity grants of 5,750 stock options and 5,750 restricted stock units. The appointment adds deep nephrology drug development expertise as the company prepares to advance its ADPKD candidate, SCY-770, into Phase 2 trials.
- Counterparty
- Steven K. Burke, M.D.